Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Aromatase Inhibitors for Breast Cancer Prevention

Cuzick, Jack · 2005 · Journal of Clinical Oncology

Abstract

Many lines of evidence point to sex hormones as the key factors in breast carcinogenesis. Classic risk factors include age at menarche, first child birth, and menopause. Estrogens, especially estradiol, appear to be the main factor. Hormone replacement therapy increases breast cancer risk, especially when the combined pills using estrogen and progesterone are used. Weight is a risk factor for postmenopausal breast cancer,wherearomatizationofandrogens inadipose tissue is the major source of estrogen. The variability of serum oestrogen levels in postmenopausal women from the lowest to highest quintile (about a six-fold difference) is associated with a two-fold variation in breast cancer risk (Fig 1). Estrogen appears to be more closely linked with breast cancer than are the other steroid sex hormones, although theymay alsohave an independent role. Lastly, fourmajor trials using the estrogen agonist, tamoxifen, to block the activity of estrogen at the receptor have shown that about 50% of estrogen receptor (ER) -positive breast cancers (Fig 2A) can be prevented, although there appears to be little effect on ER-negative breast cancer (Fig 2B), leading to a 38% overall reduction in breast cancer. Although the use of tamoxifen has been effective in reducing the incidence of breast cancer, both in the contralateral breast for women with early breast cancer, and for those at high risk who have not had the disease, it is not without side effects, especially thromboembolic events and gynecologic symptoms, and this limits its utility in a prevention setting. Recently, the third-generation aromatase inhibitors (AIs) have been introduced into the treatment of breast cancer, and their greater efficacy compared to tamoxifen, along with a more favorable side-effect profile, make them attractive agents for use in breast cancer prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.11.027

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 161

Metadata

Authors
Cuzick, J.
Venue
Journal of Clinical Oncology
Published
2005-03-10
Volume
23
Issue
8
Pages
1636-1643
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2134113023
Cited by
161
References
2
FWCI
12.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aromatase Inhibitors for Breast Cancer Prevention. https://app.cochat.ai/papers/10.1200/jco.2005.11.027
The paper
Cuzick, J. (2005). Aromatase Inhibitors for Breast Cancer Prevention. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.11.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.